Alexandra Oltová

486 total citations
22 papers, 302 citations indexed

About

Alexandra Oltová is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Alexandra Oltová has authored 22 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 9 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in Alexandra Oltová's work include Chronic Lymphocytic Leukemia Research (10 papers), Cancer-related Molecular Pathways (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Alexandra Oltová is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Cancer-related Molecular Pathways (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Alexandra Oltová collaborates with scholars based in Czechia and United States. Alexandra Oltová's co-authors include Jiřı́ Mayer, Yvona Brychtová, Martin Trbušek, Michael Doubek, Šárka Pospı́šilová, Marek Mráz, Karla Plevová, Jana Šmardová, Nikola Tom and Kateřina Staňo Kozubík and has published in prestigious journals such as Blood, Leukemia and Oncotarget.

In The Last Decade

Alexandra Oltová

21 papers receiving 299 citations

Peers

Alexandra Oltová
B D Young United Kingdom
G. García-Manero United States
Julia Romani Germany
Michael Keating United States
Steve Pavletic United States
Camino Estivill Spain
R Hehlmann Germany
Isabelle Dervite France
Loucheux-Lefebvre Mh France
D Falzetti Italy
B D Young United Kingdom
Alexandra Oltová
Citations per year, relative to Alexandra Oltová Alexandra Oltová (= 1×) peers B D Young

Countries citing papers authored by Alexandra Oltová

Since Specialization
Citations

This map shows the geographic impact of Alexandra Oltová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexandra Oltová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexandra Oltová more than expected).

Fields of papers citing papers by Alexandra Oltová

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexandra Oltová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexandra Oltová. The network helps show where Alexandra Oltová may publish in the future.

Co-authorship network of co-authors of Alexandra Oltová

This figure shows the co-authorship network connecting the top 25 collaborators of Alexandra Oltová. A scholar is included among the top collaborators of Alexandra Oltová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexandra Oltová. Alexandra Oltová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Khirsariya, Prashant, Marek Borský, Jan Verner, et al.. (2019). Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. Haematologica. 104(12). 2443–2455. 22 indexed citations
2.
Réblová, Kamila, Veronika Svobodová, Lenka Radová, et al.. (2018). Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia. Annals of Hematology. 98(2). 423–435. 1 indexed citations
3.
Veselý, Pavel, Alexandra Oltová, Marek Borský, et al.. (2016). Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells. Oncotarget. 7(38). 62091–62106. 17 indexed citations
4.
Pagáčová, Eva, Martin Falk, Iva Falková, et al.. (2014). Frequent Chromatin Rearrangements in Myelodysplastic Syndromes – What Stands Behind?. Folia Biologica. 60. S1–S7. 3 indexed citations
5.
Malčíková, Jitka, Kateřina Staňo Kozubík, Boris Tichý, et al.. (2014). Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia. 29(4). 877–885. 106 indexed citations
6.
Kantorová, Barbara, Jitka Malčíková, Jana Šmardová, et al.. (2014). TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods. Tumor Biology. 36(5). 3371–3380. 9 indexed citations
7.
8.
Némethová, Veronika, Petr Kuglík, Karla Plevová, et al.. (2013). Chromosome Banding Analysis of Peripheral Blood Lymphocytes Stimulated with IL-2 and CpG Oligonucleotide DSP30 in Patients with Chronic Lymphocytic Leukemia. Klinicka onkologie. 26(4). 263–270. 1 indexed citations
9.
Němec, Pavel, Zuzana Zemanová, Petr Kuglík, et al.. (2011). Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leukemia & lymphoma. 53(5). 920–927. 34 indexed citations
10.
Mejstříková, Ester, Eva Froňková, Tomáš Kalina, et al.. (2010). Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria. Haematologica. 95(6). 928–935. 42 indexed citations
11.
Grešlíková, Henrieta, Pavel Němec, Alexandra Oltová, et al.. (2010). Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation. Neoplasma. 57(2). 111–117. 15 indexed citations
12.
Žáčková, Daniela, Hana Klamová, Ladislav Dušek, et al.. (2010). Imatinib as the first‐line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?. American Journal of Hematology. 86(3). 318–321. 12 indexed citations
13.
Pavelka, Zdeněk, et al.. (2008). [Radiotherapy induced glioblastoma in a child previously treated for cerebellar medulloblastoma (case report and review of the literature)].. PubMed. 21(1). 31–4. 1 indexed citations
14.
Loja, Tomáš, Petr Kuglík, Alexandra Oltová, et al.. (2007). The optimization of sample treatment for spectral karyotyping with applications for human tumour cells. Cytogenetic and Genome Research. 116(3). 186–193. 3 indexed citations
15.
Bajčiová, Viera, et al.. (2007). Sarkomy měkkých tkání u adolescentů. 2(6).
16.
Němec, Pavel, Henrieta Grešlíková, Vladimíra Vranová, et al.. (2007). Comparison of prognostic impact of chromosome 1q21 gain inpatients with multiple myeloma treated by Velcade, thalidomideand any conventional therapy. 49–49. 1 indexed citations
17.
Němec, Pavel, Petr Kuglík, Vladimíra Vranová, et al.. (2007). P140 Prognostic impact of 1q21 amplification in patients with multiple myeloma treated by velcade, thalidomide and any conventional chemotherapy. Blood Reviews. 21. S131–S131. 1 indexed citations
18.
Zemanová, Zuzana, K Michalová, Marie Jarošová, et al.. (2006). Clinical Relevance of Complex Chromosomal Aberrations in Bone Marrow Cells of 107 Children with ETV6/RUNX1 Positive Acute Lymphoblastic Leukemia (ALL).. Blood. 108(11). 2278–2278. 2 indexed citations
19.
Hájek, Roman, Daniela Žáčková, Tomáš Büchler, et al.. (2003). Treatment of Chronic Myeloid Leukemia with Autologous. Medical Oncology. 20(1). 69–76. 1 indexed citations
20.
Michalová, K, Zuzana Zemanová, Jana Březinová, et al.. (2002). Location of the BCR/ABL Fusion Genes on Both Chromosomes 9q34 in Ph Negative Chronic Myeloid Leukemia. Leukemia & lymphoma. 43(8). 1695–1700. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B D Young Breakdown of academic impact, for papers by G. García-Manero Breakdown of academic impact, for papers by Julia Romani Breakdown of academic impact, for papers by Michael Keating Breakdown of academic impact, for papers by Steve Pavletic Breakdown of academic impact, for papers by Camino Estivill Breakdown of academic impact, for papers by R Hehlmann Breakdown of academic impact, for papers by Isabelle Dervite Breakdown of academic impact, for papers by Loucheux-Lefebvre Mh Breakdown of academic impact, for papers by D Falzetti
Rankless by CCL
2026